Chemed Corporation (CHE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Chemed used its Bank of America Healthcare Conference presentation to discuss VITAS hospice operations, with management saying it had more visibility after the first quarter of the Medicare cap year and had raised its census growth outlook. The discussion focused on confidence in managing Florida Medicare cap exposure while continuing census growth. The article is a conference Q&A with limited new quantitative disclosure, so near-term market impact appears modest.

Analysis

The key signal is not the near-term census commentary itself, but that management is implicitly treating Florida cap management as a controllable operating variable rather than a structural constraint. That matters because hospice is a density business: once fixed branch overhead is covered, incremental admissions have very high operating leverage, so even modest census acceleration can compound EBITDA faster than revenue. If they are confident enough to raise outlook after seeing the first quarter of the cap year, the market should start to price a lower probability of a second-half margin giveback.

The second-order effect is competitive. Smaller hospice operators with weaker referral relationships or less geographic density are more exposed to cap volatility, so CHE may gain share if it can keep admissions flowing without sacrificing compliance. That can show up with a lag in referral networks: hospital discharge planners and SNFs prefer operators that look operationally stable, which can become a multi-quarter advantage once cap headlines fade.

The main risk is that this is still a regulated-volume story, not a pure growth story. If utilization trends soften, Medicare reimbursement assumptions change, or cap math tightens again late in the fiscal year, the operating leverage can reverse quickly; that risk is most acute over the next 2-3 quarters, not years. In the non-hospice business, the market may be underestimating how much the healthcare narrative can dominate valuation until the cap overhang is fully resolved, keeping the multiple from rerating even if execution improves.

Contrarian view: the setup may actually be better than consensus thinks because the stock likely trades on fear of cap-driven earnings volatility, while the underlying franchise has asymmetric upside if census growth persists. That means the best risk/reward may come from using any pullback tied to macro/provider weakness as an entry point rather than chasing strength after every guidance raise.

Key Decisions for Investors

• Long CHE on 3-6 month horizon on any post-conference weakness; thesis is that improved Florida cap control supports multiple stability and incremental census upside can leverage margins faster than expected. Risk: a late-year cap reset or hospice volume slowdown could compress the rerating.
• Buy CHE common vs short a weaker hospice/operator peer basket over the next 1-2 quarters; CHE has more operating leverage and better ability to absorb cap volatility, while smaller peers are more exposed to referral slippage and compliance noise.
• If CHE rallies on renewed guidance confidence, consider selling covered calls 1-2 expiries out to monetize elevated implied volatility; the stock may still be range-bound until investors see several months of clean cap execution.
• Monitor quarterly census trends and Florida cap commentary closely; if management maintains raised outlook through the next update, add to the position, but trim on any indication that growth is being pulled forward at the expense of future cap pressure.